EXPLORE!

WHO recommends dapivirine vaginal ring for HIV prevention among women at considerable risk

  788 Views

#Business And Medicine  #HIV AIDS  #Infectious Diseases  #Obstetrics and Gynecology  #Pathology and Lab Medicine  #Pharmacist  #Public Health 

eMediNexus    27 January 2021

The World Health Organization (WHO) has recommended the use of dapivirine vaginal ring (DPV-VR) as an added option for women at considerable risk of HIV infection. DPV-VR has to be used as a component of combination approaches for the prevention of HIV infection.

It was noted in two Phase III randomized controlled trials that the use of DPV-VR diminished the risk of HIV infection among women and long-term use of the treatment approach was well-tolerated. In the Ring Study, there was an HIV risk reduction of 35% for women who used DPV-VR, while the ASPIRE study demonstrated a risk reduction of 27%.

The ring has to be worn inside the vagina for 28 days, following which it has to be replaced with a new ring. This silicone ring can be easily bent and inserted. It releases the drug dapivirine into the vagina gradually over a period of 28 days… (WHO, January 26, 2021)

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.